The purpose of this study is to test whether an early metabolic response, measured by PET/CT scan after the first cycle of chemotherapy, is able to predict which patients with advanced CRC have a better prognosis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
260
PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
as prescribed by oncologist
Istituto Nazionale dei Tumori
Napoli, Italy
change from baseline in highest value SUVmax (maximum standardized uptake values in PET/CT scan)
To validate as prognostic factor, in terms of overall survival,early metabolic response, defined as a reduction of more than 50% of the highest value of SUVmax recorded at PET/CT scan after one cycle of chemotherapy, compared to the highest value of SUVmax recorded baseline examination
Time frame: 2 weeks
Change from baseline in SUVmaxsum, TLGmax and TLGmaxsum
to describe and validate early metabolic response as a prognostic factor (in terms of progression free survival), using the sum of the SUVmax (SUVmaxsum) , the highest value of TLG (TLGmax), the sum of TLG ( TLGmaxsum).
Time frame: one year
correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with progression-free survival after first-line pharmacologic therapy
prognostic role of early metabolic response (defined according the above reported 4 parameters) in terms of progression free survival after a first line pharmacologic therapy
Time frame: one year
correlation among SUVmax, SUVmaxsum, TLGmax, TLGsum with objective response
To describe the association between early metabolic response (defined according the above reported 4 parameters) and objective response according RECIST criteria, measured after 3 cycles of chemotherapy
Time frame: 3 months
prognostic value of metabolic response (SUVmax, SUVmaxsum, TLGmax, TLGsum) and recist response
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.